This study aimed to assess the efficacy and safety of esaxerenone (CS-3150) in treating primary hypertension. PubMed (Medline), Cochrane Central Register of Controlled Trials (CENTRAL), and Embase databases were searched for articles published until April 18, 2023. The outcomes included were diastolic blood pressure (DBP), systolic blood pressure (SBP), 24 h DBP, 24 h SBP, and adverse events. The meta-analysis was conducted using RevMan 5.3. This study included three trials. CS-3150 5 mg had a greater effect on lowering the SBP, DBP, 24 h SBP, and 24 h DBP than either CS-3150 2.5 mg or eplerenone 50 mg. In contrast, CS-3150 2.5 mg and eplerenone 50 mg showed no significant difference in lowering DBP, SBP, 24 h DBP, and 24 h SBP. Moreover, adverse events occurred at comparable rates in the three groups. CS-3150 (especially CS-3150 5 mg) is an effective and safe treatment for primary hypertension; which can reduce blood pressure and alleviate hypertensive symptoms.

本研究旨在评估esaxerenone (CS-3150)治疗原发性高血压的有效性和安全性。检索了 PubMed (Medline)、Cochrane 对照试验中央注册库 (CENTRAL) 和 Embase 数据库，查找截至 2023 年 4 月 18 日发表的文章。结果包括舒张压 (DBP)、收缩压 (SBP)、24 小时 DBP 、24 小时收缩压和不良事件。使用 RevMan 5.3 进行荟萃分析。这项研究包括三项试验。与 CS-3150 2.5 mg 或依普利酮 50 mg 相比，CS-3150 5 mg 对降低 SBP、DBP、24 h SBP 和 24 h DBP 的效果更大。相比之下，CS-3150 2.5 mg 和依普利农 50 mg 在降低 DBP、SBP、24 h DBP 和 24 h SBP 方面没有显着差异。此外，三组中不良事件的发生率相当。CS-3150（尤其是CS-3150 5 mg）是治疗原发性高血压的有效且安全的药物；可以降低血压，缓解高血压症状。